Live news related to GENFIT stock (FR0004163111): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
GENFIT recorded a revenue of €65.4 million in 2025, boosted by royalties from Iqirvo (€21.8 million) and two milestone payments (€43.6 million) linked…
GENFIT announces that the U.S. Food and Drug Administration has granted Orphan Drug Designation (ODD) to G1090N (nitazoxanide), its experimental candi…
Genfit has received orphan drug designation from the FDA for NTZ in the treatment of acute hepatic failure on cirrhosis (ACLF). This designation, anno…
GENFIT saw an increase of 3.53% this Thursday morning, reaching 8.94 euros, bringing its quarterly performance to over 84%. The stock of the biopharma…
GENFIT reaches a new milestone this Thursday, February 19, hitting a high since the April 2020 drop during the Covid crisis. The Lille-based biotech's…
Oddo BHF établit une recommandation surperformer sur Genfit et fixe un objectif de cours à 15 €.
GENFIT will receive a milestone payment of $20 million following the surpassing of $200 million in net sales for Iqirvo® in its first full year of com…
On January 7, the biopharmaceutical group Genfit released its financial calendar for the year 2026, according to a statement distributed to investors.
According to a press release from GENFIT, GNS561 has demonstrated promising antitumor activity when used in combination therapy.
The biopharmaceutical company GENFIT (Euronext and Nasdaq: GNFT) announces that the voluntary withdrawal of its American Depositary Shares (ADS) from …
